Daré Bioscience (DARE) Scheduled to Post Earnings on Thursday

Daré Bioscience (NASDAQ:DARE) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Daré Bioscience (NASDAQ:DARE) last released its earnings results on Monday, August 12th. The biotechnology company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $2.09. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.60 million. On average, analysts expect Daré Bioscience to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Daré Bioscience Stock Up 0.2 %

DARE stock opened at $4.41 on Wednesday. Daré Bioscience has a 52 week low of $3.05 and a 52 week high of $7.56. The business has a 50-day simple moving average of $3.54 and a 200 day simple moving average of $3.92. The company has a market cap of $37.71 million, a PE ratio of -3.92 and a beta of 1.34.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on DARE shares. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Daré Bioscience in a research report on Thursday, October 24th. Maxim Group restated a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.